TCGA-ZF-A9RF-01A-11R-A38B-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 64.02759527
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.580
- G2M_CHECKPOINT+0.490
- ALLOGRAFT_REJECTION+0.460
- MYC_TARGETS_V1+0.460
- MYC_TARGETS_V2+0.400
- INTERFERON_GAMMA_RESPONSE+0.370
- INTERFERON_ALPHA_RESPONSE+0.350
- DNA_REPAIR+0.340
- IL6_JAK_STAT3_SIGNALING+0.330
- UNFOLDED_PROTEIN_RESPONSE+0.320
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.460
- MYOGENESIS-0.320
- APICAL_SURFACE-0.310
- KRAS_SIGNALING_DN-0.310
- NOTCH_SIGNALING-0.310
- ESTROGEN_RESPONSE_EARLY-0.250
- ESTROGEN_RESPONSE_LATE-0.220
- P53_PATHWAY-0.220
- WNT_BETA_CATENIN_SIGNALING-0.190
- APICAL_JUNCTION-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-00203 | — | cohortA1 | 0.874 |
| 2 | TCGA-52-7812-01A-11R-2125-07 | — | cohortA1 | 0.873 |
| 3 | e8381a92.5379.4ece.8414.230d0f0026e1 | — | cohortA1 | 0.862 |
| 4 | TCGA-38-4625-01A-01R-1206-07 | — | cohortA1 | 0.854 |
| 5 | 9a1be9ca-1641-4eac-beb9-3b54ec277a7c | — | — | 0.850 |
| 6 | TCGA-AN-A0AJ-01A-11R-A00Z-07 | — | C | 0.850 |
| 7 | TCGA-FD-A3B6-01A-21R-A20F-07 | — | — | 0.847 |
| 8 | X29cb9797.16bb.49a5.bb14.fd9e9d48bbb4 | — | cohortA1 | 0.842 |
| 9 | TCGA-AR-A1AI-01A-11R-A12P-07 | — | E | 0.840 |
| 10 | TCGA-C8-A1HM-01A-12R-A137-07 | — | C | 0.839 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.580 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.490 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.460 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.460 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.370 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.350 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.340 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.330 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.320 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.280 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.240 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.210 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.180 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.180 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.160 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.150 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.130 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.130 | Temsirolimus | — uncovered |